SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)
Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment.
Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Terminated
Sponsor's decision due to slow enrollment rate.
Other terminated trials from Aziende Chimiche Riunite Angelini Francesco S.p.A
More terminations from Aziende Chimiche Riunite Angelini Francesco S.p.A
Other Bipolar Disorder trials with similar outcome
This PHASE4 trial investigates Bipolar Disorder and is currently terminated or withdrawn. Aziende Chimiche Riunite Angelini Francesco S.p.A leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Oct 2018 — Feb 2020 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- Mediolanum Cardio Research
For direct contact, visit the study record on ClinicalTrials.gov .